The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone ( 
the role of post-transplantation maintenance therapies. 5, 6 A major question is the optimal timing of transplantation. This question is currently the subject of a US National Intergroup Study comparing early with late transplantation. One report suggested that early and late transplantation do not differ appreciably in actuarial median survival. 7 It is clear that there are multiple problems associated with patients who have relapsed and then elect to undergo stem cell mobilization and collection. Patients who have been heavily pretreated have great difficulty in mobilizing enough stem cells to ensure prompt and sustained engraftment. 8 Moreover, patients whose cells are harvested later in the disease tend to have high levels of contamination of the apheresis product with clonogenic plasma cells. 9 Ideally, in studying late transplantation, stem cell apheresis should be performed early in the disease when the tumor burden is at a minimum and before exposure to agents that would impede collection of adequate numbers of stem cells. 10 We report our experience on the outcome of patients whose stem cells were collected early in the course of disease and transplanted either at first progression or earlier if the patients were refractory to induction chemotherapy. This cohort is limited to patients who had stem cells collected early in the course of disease.
Patients and methods
Patients included in this protocol had multiple myeloma diagnosed by established criteria and underwent blood stem cell collection and cryopreservation within 12 months after their first exposure to cytotoxic chemotherapy. The transplantations were performed between June 1991 and December 1998. The shortest and median follow-ups of the survivors are 6.5 and 46 months, respectively. All patients gave written informed consent. The consent form was approved by the Mayo Institutional Review Board. No patients were lost to follow-up. There were 64 patients who fulfilled the criteria of symptomatic myeloma with stem cell collection within 12 months of diagnosis. Patients with smoldering multiple myeloma not requiring immediate chemotherapy were not included. Sixteen of the patients had received melphalan therapy (dose range, 50 to 224 mg; median, 112 mg) before evaluation at Mayo. Six were primary refractory, seven had transplantation at relapse on therapy, and three had transplantation at relapse off therapy. Statistical analysis showed no significant differences Bone Marrow Transplantation between the patients who had previously received melphalan and those who were previously untreated in terms of whether they were primary refractory, relapsing on therapy, or relapsing off therapy (Kruskal-Wallis P Ͼ 0.05).
Patients were placed initially on vincristine, doxorubicin, and dexamethasone (VAD) infusional chemotherapy for four cycles. The dexamethasone was administered as originally described at 40 mg/day on days 1-4, 9-12, and 17-20 for all four treatment cycles. 11 After the completion of VAD chemotherapy, stem cells were collected by using cyclophosphamide 1.5 g/m 2 per day for 2 consecutive days beginning with GM-CSF at 5 g/kg on day 3 and continuing through the granulocytopenic interval for 44 patients. Apheresis was performed when the total white blood cell count exceeded 500/l. Growth factor alone was given to 19, with apheresis beginning on the fifth day. Each leukapheresis procedure was scheduled to run for 4 h, processing an average of 14 l of blood per procedure. 
CD34
+ cells/kg. Conditioning was based on whether the patient had prior radiation therapy that would preclude the administration of total body radiation. Each patient was evaluated by one of us (MGC) for eligibility to receive radiation therapy, and if total body radiation could not be safely administered, high-dose melphalan was given at 200 mg/m 2 on day −1. Patients eligible for total body radiation received melphalan at 140 mg/m 2 on day −4, followed by total body radiation of 2 Gy twice daily on days −3 to −1.
Timing of transplant
After the stem cells were successfully mobilized and cryopreserved, patients who did not fulfill the criteria of objective response as defined by the Leukemia Myeloma Task Force had immediate transplantation. 12 The remaining patients were placed on vincristine, BCNU, melphalan, cyclophosphamide, and prednisone (VBMCP) chemotherapy or melphalan and prednisone in standard doses for 12 cycles of treatment 13, 14 at the discretion of the referring physician. At the completion of the 12 cycles, all therapy was discontinued, and no maintenance interferon was used. Patients who showed evidence of disease progression, defined as a 50% increase of the M protein from plateau at any time during or after maintenance chemotherapy, underwent transplantation.
Data analysis
Statistical analysis was performed using the Kaplan-Meier method. 15 Multivariate analysis was performed using the proportional hazards model of Cox. 16 All P values were calculated by log-rank testing. Differences among the three subgroups for nominal variables were assessed by 2 contingency tables. All numeric laboratory data were assessed as a continuous variable. No patients were excluded from analysis. Definition-of-response criteria post transplant were those recently published by the Myeloma Cell Committee of the European Group for Blood and Marrow Transplantation, the Chronic Leukemia Working Party, and the Myeloma Working Committee of the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. 17 In accord with the response criteria, a complete response required complete eradication of any monoclonal protein in both serum and urine as detected by immunoelectrophoresis and immunofixation. A post-transplant bone marrow had to show less than 5% plasma cells for a patient to qualify as a complete responder.
Results
The characteristics of the 64 patients who received transplants are given in Table 1 . Patients with smoldering multiple myeloma or a solitary plasmacytoma were not considered in this analysis. For the purpose of calculation of survival, patients with an antecedent smoldering myeloma or solitary plasmacytoma were not considered to have active multiple myeloma until the first day of initiation of chemotherapy for active systemic disease. In this group of 64, 14 failed to respond to induction VAD chemotherapy and had immediate transplantation (Table 2) . Twenty patients showed progression of disease while on maintenance chemotherapy with either VBMCP or melphalan and prednisone. Thirty patients completed the scheduled 12 cycles and subsequently progressed off therapy and then received transplants. As noted in Table 1 , more than 90% of the patients had multiple myeloma bone disease defined by the presence of lytic lesions characteristic of myeloma or pathologic compression fractures of the spine or long bones. The biochemical characteristics of the patients who received transplants are given in Table 2 . Seventy percent of patients had an increased ␤ 2 -microglobulin value, and nearly half had kinetically aggressive disease, as indicated by an increased plasma cell labeling index (slide based). The median number of bone marrow plasma cells at transplantation was 30%. The Durie-Salmon stage at transplantation was IIA-13, IIIA-46, and IIIB-5. Engraftment was prompt in virtually all patients. There was no relationship between the amount of melphalan administered after stem cells were cryopreserved and number of days to engraftment. This suggests that VBMCP and melphalan and prednisone have no impact on the bone marrow microenvironment. Neutrophil engraftment to an ANC of 500/l took from 7 to 23 days (median, 9 days). There were no failures of neutrophil engraftment. The time to engraftment of 50 000 platelets was 7 to 62 days (median, 13 days), with one patient failing to engraft platelets. The duration for which the stem cells were cryopreserved had no impact on engraftment. There were five patients whose stem cells were cryopreserved for more than 3 years before transplantation, and engraftment was prompt: ANC of 500/l at 9 to 12 days (median, 9 days) and platelets of 50 000/l at 11 to 26 days (median, 15 days). There were two treatment-related deaths, giving an overall treatmentrelated mortality of 3%. Both patients had primary refractory disease. One with plasma cell leukemia at the time of transplantation died on day 24 of CMV pneumonia, and fatal enterococcal bacteremia developed on day 28 in the second.
An objective response was seen in 62 of 64 patients; 21 achieved a complete response (34%). At the time of this report, 33 of the 64 patients have died (of myeloma in 22, infection in seven, renal failure in two, cardiac causes in one, and hemorrhage in one), and 22 of the 64 are progression-free. The actuarial median survival for all patients Bone Marrow Transplantation from diagnosis was 51 months (Figure 1 ). Actuarial median survival from day zero of transplantation was 19.6 months, and progression-free survival post transplantation was 11.4 months. The number of months from diagnosis to bone marrow transplantation was a median of 19.5 months: 7.4 months in the patients refractory to VAD chemotherapy and 24 months in patients who received transplants at first progression. Univariate analysis of laboratory and clinical variables (Table 3 ) demonstrated that overall survival from transplantation was impacted by age, creatinine, ␤ 2 -microglobulin, C-reactive protein, the presence of abnormal cytogenetics, the plasma cell labeling index, the percentage of plasma cells in the bone marrow pretransplant, the status at transplantation, and the presence of circulating plasma cells in the apheresis harvest. Multivariate analysis revealed that only the status at bone marrow transplantation and the presence of circulating plasma cells in the apheresis product influenced overall survival. Because the ability to analyze a mononuclear cell preparation for cytoplasmic immunoglobulin-positive plasma cells is not widely available at all institutions, the analysis was performed excluding presence of plasma cells in the apheresis product. Excluding this variable, status at transplantation and C-reactive protein were the only variables that predicted survival in the multivariate model (Figure 2 ). The Figure demonstrates superior results for patients relapsing off treatment and undergoing transplantation compared with those patients relapsing on therapy, referred to by others as refractory relapse.
Progression-free survival was analyzed in the univariate model, and important factors included the serum creatinine level, the presence of abnormal cytogenetics, the plasma cell labeling index, the percentage of plasma cells in the bone marrow at transplantation, the status at transplantation and the percentage of circulating plasma cells in the apheresis product. When these variables were placed into a Cox multivariate model, only the status at transplantation, the labeling index, and the presence of circulating plasma cells in the apheresis product predicted survival (Figure 3) . Again, because tests for circulating plasma cells are not readily available at other centers, the analysis was redone excluding this variable. Then, the status at transplantation and the labeling index were the only variables that predicted progression-free survival. No other variables influenced progression-free or overall survival. 
Discussion
In hematologic malignancies which are curable, it has been demonstrated that transplantation should occur at or near diagnosis, before the development of multidrug resistance with cytogenetic abnormalities in the malignant clone. Therefore, studies have demonstrated superior survival in patients with chronic granulocytic leukemia receiving either interferon 18 or allogeneic transplant 19 or autologous transplant 20 during the first chronic phase. 21 Similarly, patients who have acute nonlymphocytic leukemia and receive transplants in first remission or early relapse have superior relapse-free and overall survival. 22, 23 For hematologic malignancies, however, that are not currently curable, the guidelines are not as clear. In chronic lymphatic leukemia, early application of chemotherapy provides no better result than observation and the initiation of chemotherapy at symptomatic progression. 24 Likewise, none of the current modalities for the management of multiple myeloma appear to be curative, with the exception of allogeneic transplantation. 25 In addition, we have seen a large number of patients who are reluctant to consider immediate stem cell transplantation as part of the management strategy of their disease but who would like to have their stem cells harvested to allow the option for the application of high-dose chemotherapy with stem cell rescue later in their disease course. Because the results with early transplantation were not obviously superior, 7 we elected to mobilize patients who had not been extensively pretreated and to have them receive transplants later in the course of the disease.
We previously reported patients who received transplants late in the course of their disease. 26, 27 Forty-six of the originally reported 75 patients are included in this paper and 29 were excluded because cells were collected more than 1 year after diagnosis. Seventeen new patients are added to the current case series to form our study group of 64 patients. The purpose of this analysis was to exclude patients who would potentially cause lead time bias 28 for more indolent disease. 29 Patients with extensive prior chemotherapy also have a higher risk of graft failure. 30, 31 Therefore, we included only patients whose cells were collected within 12 months of diagnosis as a more homo-geneous group. The statistical analysis of this cohort was expanded to look at the presence of circulating plasma cells in the apheresis product.
Stem cell transplantation for primary refractory disease or for those who relapse off therapy appears to be a reasonable option. The short survival of those patients who relapsed on therapy was only 12 months, and it is not clear that these patients did any better than they would have done with more conventional salvage chemotherapy at a moderate dose. Patients with a resistant relapse do not appear to be ideal candidates for consideration of stem cell transplantation. Moreover, patients who relapsed off treatment were heterogeneous, because some of them may have been sensitive to a second course of standard-dose chemotherapy before transplant (sensitive relapse) and others may have been in resistant relapse. Because a second-line chemotherapy regimen was not attempted, we are unable to subdivide the group of patients relapsing off therapy into those who are and are not chemotherapy responsive. The treatment-related mortality of 3% would be considered acceptable by most centers, 32 particularly because both deaths occurred in patients with primary refractory multiple myeloma. Moreover, the duration of cryopreservation of stem cells and the amount of alkylating agent chemotherapy given after stem cells are cryopreserved appear to have no impact on engraftment kinetics. Our patients' median survival of 51 months is shorter than has been reported from other transplant centers, but the patient population may vary from center to center. This study cannot directly answer the question regarding the optimal timing of transplantation.
Our complete response rate of 34% appears comparable to complete response rates reported from centers where patients receive transplants in plateau phase of their disease. There were no differences in the complete response rates in the three groups: four of 14 primary refractory, 12 of 30 relapsing off therapy, and five of 15 relapsing on therapy. One important finding is the short progression-free survival of Ͻ1 year. Typically reported progression-free survivals are in excess of 2 years in patients who receive transplants early. 33 This suggests fundamental changes after relapse from maintenance chemotherapy. This may be reflected by the high proportion of patients with abnormal cytogenetics in our group (44%).
The outcome after transplantation was similar for patients who had primary refractory disease (ie failing to achieve a 50% M-protein reduction after four cycles of VAD) or who relapsed off therapy (Figure 2 ). This suggests that the criteria used for determining suitability for transplantation in non-Hodgkin lymphoma 34 are not applicable to multiple myeloma patients. We found no relationship between a patient's response to VAD induction chemotherapy and the subsequent outcome after high-dose chemotherapy with stem cell rescue. Therefore, it is important not to exclude patients who fail VAD from consideration of transplantation, which results in excellent overall survival.
The finding that status at transplant influences overall survival has been reported. Our term 'relapse on therapy' has been used at MD Anderson as refractory relapse and has been associated with poor outcome. 35 The finding of circulating plasma cells in the apheresis product leading to shortened survival has been reported. Conceivably, the Bone Marrow Transplantation presence of circulating plasma cells can be a reflection of disease activity, with patients who have more aggressive disease having circulating plasma cells. 36 Transplantation of myeloma patients with selected CD34 + cells does not prolong disease-free or overall survival. [37] [38] [39] When circulating plasma cells were omitted, the Creactive protein became an important indicator of adverse outcome. It has been proposed that C-reactive protein and ␤ 2 -microglobulin can be used to define the prognosis in patients with multiple myeloma. 40 In conclusion, the median survival of myeloma patients from diagnosis who have stem cells collected early in the course of the disease but who do not receive transplants in plateau phase does not appear to be different from that reported by centers where transplantation is undertaken in plateau phase. The status of the patient at the time of transplantation, the plasma cell labeling index and circulating plasma cells in the apheresis product have a major impact on outcome. Although response rates are high, response duration is short, and better techniques are required to maintain this state of minimal residual disease. An attempt is under way to maintain the plateau post transplant with dendritic cell immunotherapy. 41 
